Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares
Belite Bio, Inc - American Depositary Shares (BLTE)
Company Research
Source: GlobeNewswire
SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has commenced an underwritten public offering of American Depositary Shares (“ADSs”), each representing one of its ordinary shares. All of the securities in the offering are to be sold by Belite Bio. In addition, Belite Bio intends to grant the underwriters a 30-day option to purchase additional ADSs at the public offering price, less underwriting discounts and commission. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Belite Bio intends to use the net proceeds of the offering for (i) commercialization preparation, including building our in-house commercializ
Show less
Read more
Impact Snapshot
Event Time:
BLTE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLTE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLTE alerts
High impacting Belite Bio, Inc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BLTE
News
- Has Belite Bio's 134% 2025 Surge Fully Reflected Its DCF and Book Value Picture [Yahoo! Finance]Yahoo! Finance
- Belite Bio (NASDAQ:BLTE) was given a new $187.00 price target on by analysts at BTIG Research.MarketBeat
- Belite Bio (NASDAQ:BLTE) had its "buy" rating reaffirmed by analysts at Benchmark Co..MarketBeat
- Belite Bio (NASDAQ:BLTE) was upgraded by analysts at Mizuho from a "hold" rating to a "strong-buy" rating.MarketBeat
- Belite Bio (NASDAQ:BLTE) was given a new $200.00 price target on by analysts at Maxim Group.MarketBeat
BLTE
Earnings
- 11/10/25 - Miss
BLTE
Sec Filings
- 12/2/25 - Form 424B5
- 12/2/25 - Form 6-K
- 12/1/25 - Form 424B5
- BLTE's page on the SEC website